The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19
Authors:
- 23 August 2024
- journal article
- research article
- Published by Elsevier in Seminars in Hematology
- Vol. 61 (5) , 321-332
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Allergy and Infectious Diseases
This publication has 138 references indexed in Scilit:
- Chimeric antigen receptor T-cell therapy after COVID-19 in refractory high-grade B-cell lymphomaInternational Journal of Hematology, 2024
- Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19JAMA Network Open, 2024
- Outcomes and risk factors of SARS‐CoV‐2 omicron variant in B‐cell lymphoma patients following CD19 targeted CAR‐T therapyCancer Medicine, 2023
- Nirmatrelvir-Ritonavir and COVID-19 Mortality and Hospitalization Among Patients With Vulnerability to COVID-19 ComplicationsJAMA Network Open, 2023
- Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 PneumoniaJAMA, 2023
- Development of a Definition of Postacute Sequelae of SARS-CoV-2 InfectionJAMA, 2023
- Immunocompromised Patients with Protracted COVID-19: a Review of “Long Persisters”Current Transplantation Reports, 2022
- The Flawed Science of Antibody Testing for SARS-CoV-2 ImmunityJAMA, 2021
- Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19JAMA, 2021
- Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanomaCancer Immunology, Immunotherapy, 2002